JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB130039

重组小鼠PD-L1蛋白

Recombinant Mouse PD-L1 protein

Be the first to review this product! Submit a review

|

(5 Publications)

Recombinant Mouse PD-L1 protein is a Mouse Fragment protein, in the 19 to 239 aa range, expressed in Escherichia coli, with >85%, suitable for SDS-PAGE, Mass Spec.

查看别名

CD274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Cd274, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1

1 Images
SDS-PAGE - Recombinant Mouse PD-L1 protein (AB130039)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Mouse PD-L1 protein (AB130039)

3ug by SDS-PAGE under reducing condition and visualized by coomassie blue stain.

关键信息

纯度

>85% SDS-PAGE

表达系统

Escherichia coli

标签

His tag N-Terminus

应用

SDS-PAGE, Mass Spec

applications

生物活性

No

访问

Q9EP73

不含动物源

No

不含载体蛋白

No

种属

Mouse

存储溶液

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 0.88% Sodium chloride, 0.32% Tris HCl

storage-buffer

style
left-column

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column
style
left-column

序列信息

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMGSHMFTITAPKDLYVVEYGSNVTMECRFPVERELDLLALVVYWEKEDEQVIQFVAGEEDLKPQHSNFRGRASLPKDQLLKGNAALQITDVKLQDAGVYCCIISYGGADYKRITLKVNAPYRKINQRISVDPATSEHELICQAEGYPEAEVIWTNSDHQPVSGKRSVTTSRTEGMLLNVTSSLRVNATANDVFYCTFWRSQPGQNHTAELIIPELPATHPPQNRTH","proteinLength":"Fragment","predictedMolecularWeight":"27.6 kDa","actualMolecularWeight":null,"aminoAcidEnd":239,"aminoAcidStart":19,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"Q9EP73","tags":[{"tag":"His","terminus":"N-Terminus"}]}]
style
left-column

性能和储存信息

运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle
False
style
left-column

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column

特殊说明

形式

Liquid

附加说明

ab130039 is purified using conventional chromatography.

style
left-column

常规信息

功能

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).

序列相似性

Belongs to the immunoglobulin superfamily. BTN/MOG family.

翻译后修饰

Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8; leading to degradation. Deubiquitinated by USP22; leading to stabilization.

亚细胞定位

Early endosome membrane

style
left-column

产品实验方案

style
left-column

靶点信息

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).
See full target information Cd274
style
left-column

文献 (5)

Recent publications for all applications. Explore the full list and refine your search

CNS neuroscience & therapeutics 30:e14829 PubMed38961264

2024

Sex differences in PD-L1-induced analgesia in paclitaxel-induced peripheral neuropathy mice depend on TRPV1-based inhibition of CGRP.

Applications

Unspecified application

Species

Unspecified reactive species

Yan Cao,Wenqi Jiang,Fang Yan,Yuyan Pan,Liba Gei,Simin Lu,Xiangnan Chen,Yang Huang,Yan Yan,Yan Feng,Qiang Li,Weian Zeng,Wei Xing,Dongtai Chen

Frontiers in endocrinology 13:913631 PubMed35846323

2022

Negative Correlation Between F-RGD Uptake PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Leilei Wu,Jingru Liu,Shasha Wang,Menglin Bai,Min Wu,Zhenhua Gao,Jianing Li,Jinming Yu,Jie Liu,Xue Meng

British journal of pharmacology 178:2651-2670 PubMed33768523

2021

Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.

Applications

Unspecified application

Species

Unspecified reactive species

Chenglong Liu,Feilong Zhou,Ziqin Yan,Lian Shen,Xichen Zhang,Fenglian He,Heng Wang,Xiaojie Lu,Ker Yu,Yujun Zhao,Di Zhu

Nature communications 11:1395 PubMed32170083

2020

An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.

Applications

Unspecified application

Species

Unspecified reactive species

Guan Wang,Xi Kang,Katherine S Chen,Tiffany Jehng,Lindsey Jones,Jie Chen,Xue F Huang,Si-Yi Chen

Science translational medicine 12: PubMed32075945

2020

Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates.

Applications

Unspecified application

Species

Unspecified reactive species

Zilong Wang,Changyu Jiang,Qianru He,Megumi Matsuda,Qingjian Han,Kaiyuan Wang,Sangsu Bang,Huiping Ding,Mei-Chuan Ko,Ru-Rong Ji
View all publications
style
left-column
style
left-column
style
right-column

搭配使用产品

Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Proteins & Peptides

AB280753

Recombinant Human PD1 protein

Mass Spectrometry - Recombinant Human PD1 protein (AB280753)

  • 0
  • 0
Primary Antibodies

AB52587

Anti-PD1 antibody [NAT105]

BOND RX™ Validated|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

  • 5
  • 9
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂，为您科研的每一步提供支持。若我们的产品未能达到预期性能，我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com